Kenvue Inc. (NYSE:KVUE) Receives $20.23 Average PT from Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have been assigned a consensus rating of “Hold” from the eighteen brokerages that are presently covering the stock, MarketBeat.com reports. Twelve investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $20.2333.

A number of equities research analysts have weighed in on the stock. JPMorgan Chase & Co. cut their price target on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Citigroup cut their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. Finally, Canaccord Genuity Group reissued a “hold” rating and set a $15.00 price objective (down from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th.

Kenvue Stock Performance

KVUE opened at $16.74 on Friday. The business has a 50 day moving average price of $16.74 and a two-hundred day moving average price of $18.48. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The company has a market capitalization of $32.07 billion, a price-to-earnings ratio of 22.32 and a beta of 0.60. Kenvue has a 1-year low of $14.02 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The company had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. During the same quarter in the previous year, the business earned $0.28 EPS. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts predict that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were given a $0.2075 dividend. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.0%. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Insiders Place Their Bets

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of the business’s stock in a transaction on Friday, December 12th. The shares were purchased at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the acquisition, the director owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in KVUE. AlphaCore Capital LLC boosted its stake in Kenvue by 9.9% in the 2nd quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock worth $111,000 after purchasing an additional 476 shares during the period. Empirical Finance LLC lifted its holdings in shares of Kenvue by 1.8% in the second quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock valued at $593,000 after purchasing an additional 491 shares in the last quarter. Proffitt & Goodson Inc. boosted its position in shares of Kenvue by 8.2% in the second quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock worth $143,000 after buying an additional 517 shares during the period. UMB Bank n.a. boosted its position in shares of Kenvue by 22.3% in the second quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock worth $60,000 after buying an additional 521 shares during the period. Finally, Altus Wealth Group LLC grew its holdings in shares of Kenvue by 1.7% during the second quarter. Altus Wealth Group LLC now owns 31,398 shares of the company’s stock valued at $657,000 after buying an additional 524 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.